AccessibilityHelpAbout Us

Scribe Therapeutics(NASDAQ) SCTX

Market Cap$502.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2026)+23%
5 YearN/A
1 YearN/A
1 Month-29%
$24.58
-7.35%
-1.95Today
Scribe Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 26.532026-09-23
Scribe Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-8.83%USD 29.102026-09-16
1 month-28.78%USD 37.252026-08-24
Since inception+22.54%USD 21.652026-07-24

Scribe Therapeutics Financials at a Glance

Market Cap

$502.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$26.17

Net Income (TTM)

-$37.15

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-6.46 (Low)

Price

$24.58

Volume

13,579.647

Open

$26.27

Previous Close

$26.53

Daily Range

$25.53 - $26.27

52-Week Range

$15.00 - $39.60

Estimated Earnings Date

Sep 2, 2026

SCTX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scribe Therapeutics

Scribe Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing in vivo CRISPR-based genetic medicines. The company focuses on engineering proprietary technologies to target genetic drivers of disease, particularly atherosclerotic cardiovascular disease (ASCVD), with the goal of transitioning treatment from chronic care to preventative intervention.

Products and Services
  • CRISPR-based genetic medicines targeting genetic diseases
  • Innovative technologies for preventative healthcare solutions
  • Focus on atherosclerotic cardiovascular disease treatments
Growth Outlook
  • Potential to revolutionize treatment paradigms in cardiovascular health
  • Strong pipeline of CRISPR-based therapies under development
  • Increasing demand for genetic medicine solutions in healthcare
Financial Highlights
  • Market capitalization of approximately $453 million
  • Stock price range between $17.31 and $39.6 over the past year
  • Average trading volume of 279,865 shares, indicating investor interest
Scribe Therapeutics is positioned at the forefront of genetic medicine, leveraging CRISPR technology to address significant health challenges. The focus on preventative interventions in cardiovascular disease aligns with growing trends in healthcare, emphasizing the importance of early treatment. With a solid market capitalization and a notable stock price range, the company reflects a promising investment opportunity in the biotechnology sector. The innovative approach to genetic therapies may attract attention from investors looking for cutting-edge solutions in healthcare.
AI Generated • Sep 22, 2026

Industry

Biotechnology

Sector

Health Care

Employees

82

CEO

Benjamin L. Oakes, PhD

Website

www.scribetx.com

Headquarters

Alameda, CA 94501, US

SCTX Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

0.00%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

$502.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

18.93M

Volume

13.58K

Avg. Volume

302.50K

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Scribe Therapeutics Performance Analysis

Scribe Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20242024-12-31USD 27,413,000N/A
20252025-12-31USD 51,174,00086.7%
Scribe Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20242024-12-31USD -2.72N/A
20252025-12-31USD -1.24-54.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$1.92

N/A

Gross Profit

$1.13

N/A

Gross Margin

59.07%

N/A

Market Cap

$502.26MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

82

N/A

Net Income

-$6.48

N/A

EBITDA

-$8.61

N/A

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$78.86

N/A

Total Debt

$43.27

N/A

Accounts Receivable

$1.11

N/A

Inventory

$0.00

N/A

Long Term Debt

$4.10

N/A

Short Term Debt

$39.17

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

-$5.35

N/A

Operating Cash Flow

-$5.34

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,714.64-0.01%
^DJIDJI
$51,582.61-0.01%
^IXICNASDAQ
$26,958.01-0.01%
BTCBitcoin
$84,184.00-0.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$35.66+5.94%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$137.23-6.17%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$35.00+2.53%
TQQQProShares Trust - ProShares UltraPro Qqq
$76.66-2.54%

Questions About SCTX

What is the current price of Scribe Therapeutics?

Scribe Therapeutics is trading at $25.55 per share.

What is the 52-week range for Scribe Therapeutics?

Over the past 52 weeks, Scribe Therapeutics has traded between $15.00 and $39.60.

How much debt does Scribe Therapeutics have?

As of the most recent reporting period, Scribe Therapeutics reported total debt of $43.27M.

How much cash does Scribe Therapeutics have on hand?

Scribe Therapeutics reported $35.59M in cash and cash equivalents in its most recent financial results.

What is Scribe Therapeutics’s dividend yield?

Scribe Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services